Published in J Cancer Res Clin Oncol on December 22, 2016
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
A comprehensive survey of Ras mutations in cancer. Cancer Res (2012) 3.67
Novel functions and signalling pathways for GDNF. J Cell Sci (2003) 2.98
Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol (2013) 2.80
Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68
RET/PTC rearrangement in thyroid tumors. Endocr Pathol (2002) 2.42
The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg (2007) 2.36
Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg (1955) 2.16
Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn (2006) 2.11
Ras oncogenes and their downstream targets. Biochim Biophys Acta (2007) 2.00
BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther (2011) 1.77
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res (2007) 1.75
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol (2010) 1.70
Papillary thyroid carcinoma: an update. Mod Pathol (2011) 1.59
Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab (2013) 1.56
Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology (2002) 1.51
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol (2012) 1.48
Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques. Clin Chem (1997) 1.46
Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol (2001) 1.43
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab (2006) 1.39
Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol (2002) 1.33
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab (2001) 1.31
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol (2006) 1.29
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer (2008) 1.26
SYTO dyes and EvaGreen outperform SYBR Green in real-time PCR. BMC Res Notes (2011) 1.23
Follicular adenoma and carcinoma of the thyroid gland. Oncologist (2011) 1.21
Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) (2006) 1.20
Molecular diagnostics for the detection and characterization of microbial pathogens. Clin Infect Dis (2007) 1.17
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood (2011) 1.16
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol (2009) 1.13
Distinct histopathological features of Hashimoto's thyroiditis with respect to IgG4-related disease. Mod Pathol (2012) 1.11
The molecular perspective: the ras oncogene. Oncologist (1999) 1.10
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol (2011) 1.10
Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol (1998) 1.05
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.05
Molecular analysis of thyroid tumors. Mod Pathol (2011) 1.04
Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene (1999) 1.02
Hashimoto's Thyroiditis: From Genes to the Disease. Curr Genomics (2011) 1.01
RAS mutations in thyroid cancer. Oncologist (2013) 1.00
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) (2012) 1.00
Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J (2010) 0.98
Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res (2013) 0.98
Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res (2012) 0.96
Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol (2004) 0.95
Roles of mutation and selection in speciation: from Hugo de Vries to the modern genomic era. Genome Biol Evol (2011) 0.95
BRAF Mutation in Colorectal Cancer: An Update. Biomark Cancer (2015) 0.95
Guidelines for the tetra-primer ARMS-PCR technique development. Mol Biotechnol (2014) 0.94
Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid (2014) 0.92
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol (2010) 0.91
Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab Invest (2004) 0.91
Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenosine receptor subtypes. Adv Biomed Res (2014) 0.90
The thyroid gland: recurring problems in histologic and cytologic evaluation. Arch Pathol Lab Med (2008) 0.89
Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma. Ann Surg Oncol (2014) 0.88
Determinants of thyroid autoantibody production in Hashimoto's thyroiditis. Expert Rev Clin Immunol (2007) 0.88
Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc (2005) 0.88
Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics (2011) 0.86
Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer. Head Neck (2015) 0.86
Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med (2015) 0.84
Scanning of beta-globin gene for identification of beta-thalassemia mutation in Romanian population. J Cell Mol Med (2004) 0.83
Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid. Int J Endocrinol (2014) 0.83
Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib. Case Rep Oncol (2014) 0.81
Designing, optimization and validation of tetra-primer ARMS PCR protocol for genotyping mutations in caprine Fec genes. Meta Gene (2014) 0.80
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol (2014) 0.80
Gene rearrangements in radiation-induced thyroid carcinogenesis. Med Pediatr Oncol (2001) 0.80
Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. Sci Rep (2015) 0.80
The immune-related role of BRAF in melanoma. Mol Oncol (2014) 0.78
The ret/PTC1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus. Thyroid (1998) 0.78
Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements. Eur J Endocrinol (2015) 0.77
An overview of mutation detection methods in genetic disorders. Iran J Pediatr (2013) 0.77
Quantitative analysis of the BRAF (V600E) mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. Int J Clin Oncol (2016) 0.76